The number of publically disclosed biosimilar development projects has increased by more than 40% in the last 12 months, according to Decision Resources Group’s (DRG) Biosimilars Advisory Service report Global Biosimilars Markets: Pipelines, Regulations, and Major Players.   While the majority of these development projects are not yet in clinical development, the 20% annual increase in the number of biosimilars in clinical trials indicates significant advancement in the late-stage pipeline, acco...